I have no doubt there are no issues on the clinical side of the business. Leslie and team have done what they can to achieve optimal results from the trials. Unfortunately, Leslie and team have no control over Big Pharma' m&a strategy. How Big Pharma choose to spend their money is beyond the control of Leslie and team.
The above is not in defence of management, but simply an understanding that reality is complex. I am just as disappointed with the share price as everyone else on here. With hindsight, should have sold more than I did near the top.
Best case scenario over the next 12 months, outside of the continued positive trial data, would be the sale of HER-Vaxx. Unfortunately, Big Pharma didn't bite, so high prices are out of the picture. $10-20 million upfront + milestone payments...maybe?
IMU Price at posting:
4.2¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)